Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma

NCT06540963 is registered in ClinicalTrials.gov with Giselle Sholler as lead sponsor.

NCT NCT06540963
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06540963 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
Lead sponsor
Giselle Sholler
Phase
Phase 2
Overall status
Recruiting
Start date
December 6, 2024
Completion date
December 1, 2035
Enrollment
98 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

neuroblastoma